Skip to content
Company Spotlight

Medpace Welcomes Dr. DeWire-Schottmiller to the Hematology/Oncology Team

  • April 28, 2021
Dr. Mariko DeWire-Schottmiller is a board-certified pediatric hematologist/oncologist with 15 years of experience in clinical research, academia, and clinical oncology practice in Oncology and Neuro-oncology.

Unique to Medpace is our emphasis on scientific and medical expertise, which is especially important for hematology/oncology clinical development, including CNS tumors. In her role as a medical monitor, Dr. DeWire-Schottmiller will help develop a strategic direction that provides medical leadership and guidance and sets the stage for your compound’s success.

In this brief interview, we learn more about her background and the expertise she brings to Medpace.

Tell us about your background: what expertise do you bring to Medpace?

I am a board-certified pediatric hematologist/oncologist with additional training in neuro-oncology.  My career was initially in academia and clinical research.  I have expertise in neuro-oncology including managing patients with aggressive CNS tumors, developing and leading phase I clinical trials in high-grade CNS tumors, collaborating with research scientists in translational research, medical monitoring in a Phase I consortium, while also focusing on maximizing patients’ quality of life in the setting of aggressive disease.

From a clinical development standpoint, what new innovations are you most excited about?

I’m most excited about working on targeted therapies across multiple diseases. There have been rapid breakthroughs in oncology research and I think it’s exciting how clinical development is catching up and becoming more efficient. Scientists are advancing the field at a rapid rate and clinical research is highly regulated. Patient safety is protected so bridging the gap is necessary for innovations to get to patients expeditiously.

What drew you to Medpace?

The opportunity to serve in advancing therapies for patients with hematologic and oncologic diseases through collaborative efforts with the Medpace team and Sponsors.  As a clinical investigator, I was aware of the urgency for clinical development in hematologic and oncologic diseases.  As the Sponsors develop breakthroughs in investigational products and therapeutic interventions, I am honored to move the Sponsors’ programs forward safely, deliberately, and expeditiously with the ultimate goal to minimize toxicities and improved survival.

Learn more about Medpace’s hematology and oncology experience.